Table 1.
Sample summary statistics among amyloid-restricted patients for both the incident and prevalent populations
| Variable | Incident | Prevalent |
|---|---|---|
| Female, % (N) | 51.4% (3610) | 51.0% (5923) |
| Age | ||
| Mean (SD) | 78.69 (10.43) | 77.72 (10.48) |
| Median (IQR) | 80.00 (14.00) | 79.00 (14.00) |
| Years of education | ||
| Mean (SD) | 14.84 (3.58) | 14.73 (3.73) |
| Median (IQR) | 16.00 (6.00) | 16.00 (6.00) |
| Concomitant symptomatic AD medication use, % (N) | 64.4% (4528) | 64.5% (7487) |
| ApoE ε4 genotype, % (N) | ||
| ε3, ε3 | 32.5% (2285) | 32.4% (3761) |
| ε3, ε4 | 35.6% (2505) | 36.2% (4206) |
| ε3, ε2 | 4.6% (326) | 4.0% (462) |
| ε4, ε4 | 11.5% (806) | 11.0% (1282) |
| ε4, ε2 | 2.4% (170) | 2.3% (266) |
| ε2, ε2 | 0.3% (20) | 0.2% (27) |
| Missing | 13.0% (915) | 13.9% (1611) |
| CDR health state, % (N) | ||
| Asymptomatic | 0.7% (50) | 2.9% (333) |
| MCI-AD | 3.1% (219) | 9.3% (1077) |
| Mild AD dementia | 6.3% (441) | 11.9% (1387) |
| Moderate AD dementia | 23.5% (1648) | 21.5% (2495) |
| Severe AD dementia | 34.1% (2394) | 30.6% (3553) |
| Died | 32.4% (2275) | 23.8% (2770) |
| Diabetes | 13.7% (752) | 13.6% (1288) |
| CVD risk factors | 78.4% (4297) | 76.6% (7257) |
| Count of CVD components | ||
| 0 | 64.7% (3547) | 66.6% (6317) |
| 1 | 19.4% (1064) | 18.7% (1774) |
| 2 | 9.2% (506) | 8.8% (832) |
| 3 | 4.3% (235) | 3.9% (372) |
| 4 | 1.5% (84) | 1.3% (125) |
| 5 | 0.6% (31) | 0.5% (43) |
| 6 | 0.3% (14) | 0.2% (15) |
| Stroke/TIA | 18% (972) | 16% (1560) |
| Sample size (observations) | 7027 | 11615 |
AD Alzheimer’s disease, ApoE apolipoprotein E, CDR Clinical Dementia Rating, CVD cardiovascular disease, IQR interquartile range, MCI-AD mild cognitive impairment due to Alzheimer’s disease, TIA transient ischemic attack
Sample reflects observations used in transition probability models